Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
This Schedule 13G/A reports that Eli Lilly & Co. and Eli Lilly S.A. filed an amendment concerning their holdings in Immunocore Holdings plc ordinary shares (CUSIP 54258D105) related to the reporting event dated 09/30/2025. Both reporting entities state they beneficially own 0 ordinary shares, representing 0.0% of the class, with 0 shares of sole or shared voting or dispositive power. The filing lists issuer headquarters at 90 Park Drive, Milton Park, Abingdon, Oxfordshire, UK. Signatures show the amendment was executed by Christopher Anderson as Attorney-in-Fact for both filers on 10/03/2025, and reference previously filed powers of attorney incorporated by reference.
Lilly Endowment Inc. reported the sale of 112,596 shares of Eli Lilly & Co. (LLY) common stock on 10/02/2025. The Form 4 lists multiple sale (S) transactions with weighted-average prices reported per line ranging from about $821.09 to $833.92 and transaction price ranges across the trades between $821.00 and $834.23. After the reported sales, the filing shows the reporting person beneficially owned 95,029,382 shares, held directly. The form is signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc., dated 10/03/2025. The filing provides weighted-average prices and footnotes saying the filer will supply per-price breakdowns on request.
Lilly Endowment Inc., a reporting person and director for Eli Lilly & Co (LLY), sold a total of 215,822 shares of Eli Lilly common stock on 10/01/2025 across multiple transactions. The sales occurred at weighted‑average prices reported per lot, with transaction price ranges disclosed between $807.85 and $833.155. After these transactions the reported beneficial ownership held indirectly by the reporting person was 95,141,978 shares. The Form 4 covers transactions numbered 31–55 of 55 total for that reporting day and was signed by Diane M. Stenson as Vice President & Treasurer on behalf of Lilly Endowment Inc.
Eli Lilly (LLY) Form 144 notifies the market of a proposed sale of 305,000 shares of common stock through J.P. Morgan Securities, with an indicated aggregate market value of $251,753,100 and an approximate sale date of 10/02/2025. The filing shows these shares were originally acquired as a gift from the J.K. Lilly Sr. Trust (acquisition date listed as 02/10/1948) and reports prior institutional sales by Lilly Endowment Inc. totaling 875,000 shares across five trades in July–October 2025, generating about $696,456,589 in gross proceeds. The filer attests no undisclosed material adverse information.
Form 144 notice filed for Eli Lilly & Co (LLY) proposing a sale of common stock. The filer notifies a broker, Fidelity Capital Markets, of an approximate sale of 295,000 shares with an aggregate market value of $225,085,000 and an approximate sale date of 10/01/2025 on NYSE/NASDAQ. The shares were reported as originally acquired by gift on 02/10/1948 from the J.K. Lilly Sr. Trust; the acquisition table lists 38,400,000 shares acquired on the donor's 01/21/1937 date. The filing also lists multiple recent sales by Lilly Endowment Inc. in July–October 2025 with individual gross proceeds shown for each trade. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information.
Lilly Endowment Inc., a reporting person and director-related holder of Eli Lilly & Co. (LLY) stock, reported multiple open-market sales on 09/30/2025. The Form 4 shows four sell transactions totaling 113,694 shares sold at weighted-average prices of approximately $763.095, $764.355, $765.44, and $766.117, executed across price ranges disclosed in footnotes. After these disposals the reporting person beneficially owned 95,492,993 shares. The filing is signed by Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc., and offers to provide transaction-level price details on request.
Lilly Endowment Inc. reported sales of Eli Lilly & Co. (LLY) common stock on 09/19/2025. The filing shows two dispositions: 22,965 shares sold at a weighted average price of $763.053, and 700 shares sold at a weighted average price of $764.473. Following these transactions the reporting person beneficially owned 95,606,687 shares (direct ownership reported). The form was signed by Diane M. Stenson, Vice President & Treasurer, on 09/22/2025.
Lilly Endowment Inc. reported the sale of 106,626 shares of Eli Lilly & Co. common stock across multiple transactions dated 09/18/2025, reducing its beneficial ownership from 95,697,115 shares to 95,630,352 shares. The Form 4 shows weighted-average sale prices in five tranches with reported averages of approximately $763.292, $764.519, $765.567, $766.451, and $767.065, with underlying per-trade price ranges disclosed in footnotes. The filing identifies the reporting person as Lilly Endowment Inc. (relationship boxes indicate Director and 10% owner) and is signed by Diane M. Stenson on behalf of the endowment.
Eli Lilly & Co (LLY) Form 144 notifies the SEC of a proposed sale of 300,000 shares of common stock through J.P. Morgan Securities LLC, listed for sale on 09/18/2025 on NYSE/NASDAQ with an aggregate market value of $228,039,000 out of 946,456,759 shares outstanding. The shares were acquired as a gift on 02/10/1948 from the J.K. Lilly Sr. Trust; the donor originally acquired 38,400,000 shares on 01/21/1937. The filer reports a prior sale in the past three months of 280,000 shares on 07/24/2025 for $225,419,292. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and carries the required signature and criminal-warning language.
Gabrielle Sulzberger, a director of Eli Lilly & Co (LLY), acquired 6.627 shares of the company on 09/15/2025 at a reported price of $748.19 per share. Following the transaction she beneficially owned 2,721.97 shares. The filing explains these shares were elected to be deferred in lieu of cash compensation under the Lilly Directors' Deferral Plan and will be settled in common stock upon her separation from service.